Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma.

Abstract

The effects of square planar rhodium, [RhacacCOD]o and iridium, [IracacCOD]o complexes and of octahedral ruthenium, [cis-RuCl2 (DMSO)4]o complex have been examined in comparison with cis-dichlorodiammino platinum(II) (cis-PDD). The toxicity in BDF1 mice varies widely and decreasing LD50-values, ranging from 0.94 mg/kg to 1000 mg/kg, have been obtained for cis-PDD, [RhacacCOD]o, [IracacCOD]o and [cis-RuCl2(DMSO)4]o, respectively. All the tested complexes similarly inhibit the growth of subcutaneous Lewis lung carcinoma and the development of spontaneous as well as of artificial metastases, with the exception of [IracacCOD]o which is inactive on metastases. The antitumor activity of [RhacacCOD]o and [cis-RuCl2(DMSO)4]o appears interesting, since it is of the same magnitude as that of cis-PDD, considering also that they were found to be only marginally nephrotoxic.

• Authors: G Sava, T Giraldi, G Mestroni, G Zassinovich
• Journal: Chemico-biological interactions (Chem Biol Interact) Vol. 45 Issue 1 Pg. 1-6 (Jul 01 1983) ISSN: 0009-2797 [Print] Ireland
• PMID: 6683595 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organometallic Compounds
• dichlorotetrakis(dimethyl sulfoxide)ruthenium II
• acetylacetonate-1,5-cyclooctadiene iridium I
• acetylacetonate-1,5-cyclooctadiene rhodium I
• Iridium
• Ruthenium
• Rhodium
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (therapeutic use, toxicity)
• Cisplatin (therapeutic use)
• Iridium (therapeutic use)
• Lethal Dose 50
• Lung Neoplasms (drug therapy, secondary)
• Mice
• Neoplasm Transplantation
• Neoplasms, Experimental (drug therapy)
• Organometallic Compounds (therapeutic use)
• Rhodium (therapeutic use)
• Ruthenium (therapeutic use)